[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645393":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":23,"locations":10,"responsibleParty":29,"collaborators":10,"id":31,"slug":10,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":32,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"ProVerum Medical","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational Group",null,"US based subjects who exited from the ProVIDE or ProVIDE II studies.",[13],"Device: ProVee Urethral Expander System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","ProVee Urethral Expander System","ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.",[9],[21,22],"ProVee Expander","ProVee",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Diane Gargus","CONTACT","1-720-472-1504","diane@proverummedical.com",{"type":30,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645393",false,"NCT07680543","ProVIDE Studies Post Exit Analysis","Inclusion Criteria:\n\n* 1\\. US based subjects previously enrolled in the ProVIDE Study or the ProVIDE II Bridging Study who had a ProVee device removed.\n* 2\\. Subjects who withdrew consent or were withdrawn by site Study PI.\n* 3\\. Subjects consented to make data available.\n\nExclusion Criteria:\n\n* 1\\. Incomplete records available.\n* 2\\. Subjects who exited the studies due to restarting BPH medication while they were enrolled.\n* 3\\. Subjects who did not receive a ProVee in the ProVIDE Study or the ProVIDE II Bridging Study.\n* 4\\. Subjects who exited the studies due to prostate cancer.","MALE","45 Years",{"count":39,"type":40},25,"ESTIMATED","OBSERVATIONAL","A study to collect data on the post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.",[44],"BPH With Symptomatic Lower Urinary Tract Symptoms",[46],"BPH \u002F LUTS","NOT_YET_RECRUITING","2026-06-25",{"date":50,"type":51},"2026-07-02","ACTUAL",{"date":53,"type":40},"2026-07-14",{"date":55,"type":40},"2029-07-31",{"name":5,"class":6}]